PHARMACY

Anoka-Ramsey now offers pharmacy technician degree

BY Ryan Chavis

CAMBRIDGE, Minn. — Anoka-Ramsey Community College announced that it will offer an associate in science degree in pharmacy technician. The required general education courses for the new program can be taken at either the Cambridge or Coon Rapids locations.

Program-specific courses are held at the Cambridge campus to help meet the needs of area pharmacies, according to the college.

“This is an exciting opportunity for both our students and business partners in the Cambridge area,” Natasha Baer, associate dean of educational services, said. “The addition of this program provides more flexible training options that lead to industry employment in a short amount of time.”

The AAS degree was created as part of a Health Professionals Pathways grant initiative to allow students to obtain credentials to work in the pharmacy field. A student may begin with Anoka-Ramsey’s Pharmacy Technician certificate, which enables the student to work in the industry. The student can then pursue the AAS degree. They also may take additional coursework to prepare for a doctor of pharmacy program.

Applications for the Pharmacy Technician program for fall 2014 semester will be accepted Feb. 1 to Feb. 28.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Avella Specialty Pharmacy recognized as one of 100 ‘Mid-Market Elite’ companies

BY Michael Johnsen

PHOENIX — Avella Specialty Pharmacy on Thursday was recognized in Chief Executive magazine’s first list of the “Mid-Market Elite.” Avella joins other highly-regarded companies, including Twitter, LinkedIn and LifeLock, in receiving this honor that is given to 100 companies. 

The winners were selected based on their strengths in the following key areas: superior growth, a track record of innovation, an exceptional corporate culture, charismatic leadership and a compelling business model. Avella Specialty Pharmacy represented the only pharmacy operator on the list. 

“It is exciting to learn that Avella has been recognized as a top performing company,” said Avella president Keith Cook. “We are honored to be included on such a prestigious list and joined by other companies that are driving innovation and excellence.”

Chief Executive magazine worked in partnership with GE Capital and the National Center for the Middle Market (Fisher School of Business) at Ohio State University to select 100 honorees from a pool of more than 197,000 public and private companies. The publication specifically called out Avella as the premier provider in the specialty pharmacy industry.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Valeant Pharmaceuticals to close Solta Medical acquisition

BY Michael Johnsen

LAVAL, Quebec — Valeant Pharmaceuticals International on Thursday announced the expiration of the tender offer by a subsidiary of Valeant Pharmaceuticals International to purchase all of the outstanding shares of Solta Medical for $2.92 per share in cash, without interest (less any applicable withholding taxes). 

The offer expired at midnight on Jan. 23, 2014. 

American Stock Transfer & Trust Company the depositary for the tender offer, has advised that, as of the expiration of the offer, a total of 68.8 million shares had been tendered into and not validly withdrawn from the offer, representing approximately 85% of Solta’s outstanding shares. 

Additionally, the depositary has advised that an additional 3.3 million shares had been tendered by notice of guaranteed delivery, representing approximately 4% of Solta’s outstanding shares. 

The condition to the offer that at least a majority of the outstanding shares of Solta common stock, not including shares tendered pursuant to procedures for guaranteed delivery and not yet delivered, be validly tendered and not properly withdrawn prior to the expiration of the offer has been satisfied. 

As a result of the merger, Solta will become a wholly owned subsidiary of VPI. In the merger, each remaining share of Solta that was not validly tendered in the offer will be cancelled and converted into the right to receive the same $2.92 per share in cash, without interest. Following completion of the merger, the common stock of Solta will no longer be listed for trading on the NASDAQ Global Select Market, which is expected to take effect as of the close of market Thursday.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES